title: [The best of cardiac rehabilitation in 2006].
abstract: The meta-analysis showing the benefits of physical training revisited: Taylor examined only the cardiac rehabilitation trials of exercise intervention alone (versus usual care) and demonstrated that cardiac mortality is 28 % reduced and exercise appears to have an independent mortality benefit. An economic evaluation of cardiac rehabilitation: a systematic review of 15 economic evaluations. Evidence to support the cost-effectiveness of supervised cardiac rehabilitation compared with usual care in myocardial infarction and heart failure was identified. But further well-designed trials are required. Pronostic value of some variables determined by exercise testing entering cardiac rehabilitation and after physical training. A beneficial effect of physical training versus usual care on BNP and neurohormones in patients with chronic heart disease. Patients on beta blockers after myocardial infarction: determination of a more accurate training heart frequency derived from the classical Karvonen's formula. The combination of trimetazidine with exercise training provides greater improvements in functional capacity, left ventricular function and the endothelium-dependent relaxation of the brachial artery than exercise training alone in patients with ischaemic cardiomyopathy referred for cardiac rehabilitation. Guidelines for resistance exercise after cardiac event: a new paradigm less restrictive, safe and efficient to accelerate patients' return to daily activities. Recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease: the result of consensus among experts from the ESC study group of sports cardiology.
authors.affiliation: Unité de readaptation cardiaque, centre convalescence et rééducation, 23. rue Gaffarel. 21000 Dijon. benedicte.verges@chu-dijon.fr
authors.forename: B
authors.initials: B
authors.lastname: Vergès
authors.forename: M C
authors.initials: MC
authors.lastname: Iliou
authors.forename: S
authors.initials: S
authors.lastname: Corone
authors.forename: B
authors.initials: B
authors.lastname: Pierre
authors.forename: Ph
authors.initials: P
authors.lastname: Meurin
authors.forename: M
authors.initials: M
authors.lastname: Fischbach
authors.forename: B
authors.initials: B
authors.lastname: Pavy
authors.forename: F
authors.initials: F
authors.lastname: Carré
authors.forename: J M
authors.initials: JM
authors.lastname: Feige
authors.forename: R
authors.initials: R
authors.lastname: Brion
authors.forename: H
authors.initials: H
authors.lastname: Douard
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002309:Cardiology / Q000639:trends; D003365:Costs and Cost Analysis; D015444:Exercise; D006331:Heart Diseases / Q000188:drug therapy / Q000191:economics / Q000534:rehabilitation*; D006801:Humans; D015201:Meta-Analysis as Topic; D011379:Prognosis
chemical_list: D000319:Adrenergic beta-Antagonists